Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD2811 Monotherapy or Combination in AML
NCT03217838Phase 1Terminated
- Sponsor
- AstraZeneca
- Start
- Jul 2017
- Primary completion
- Mar 2021
- Modality
- Nanoparticles, Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of defosbarasertib in acute myeloid leukemia (AML) (6 arms), sponsored by AstraZeneca. Primary endpoints: Dose-limiting Toxicities, Treatment Emergent Adverse Events and 1 more. Started Jul 2017; status: terminated.
02
Drugs
defosbarasertib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03217838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03217838.